Search En menu en ClientConnect
Top 5 search results See all results Advanced search
Top searches
Most visited pages
    Reference: 20180275
    Release date: 30 January 2019

    Promoter – Financial Intermediary




    The project concerns Research and Development (R&D) investments in core therapeutic areas to be implemented in the period 2018-2020 .


    The investments cover RDI expenditures of the clinical and regulatory development of Orion's product range. By co-investing in this project, the EIB contributes to make treatments available for diseases that are a high priority for the healthcare system and enables the creation of scientific knowledge.


    • Services - Professional, scientific and technical activities

    Proposed EIB finance (Approximate amount)

    EUR 100 million

    Total cost (Approximate amount)

    EUR 336 million

    Environmental aspects

    All of the project activities are expected to be carried out in existing facilities and laboratories without changing their already authorised scope and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU, as amended. Nevertheless, the Bank's services will review during the project appraisal whether any of the investments require an EIA, as well as any other environmental details of the project.


    The promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not subject to the EU directives on procurement.


    Signed - 18/01/2019


    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Related tags

    Finland Services